CA2887056C - Monohydrate crystal of fimasartan potassium salt, method for preparing same, and pharmacological composition comprising same - Google Patents

Monohydrate crystal of fimasartan potassium salt, method for preparing same, and pharmacological composition comprising same Download PDF

Info

Publication number
CA2887056C
CA2887056C CA2887056A CA2887056A CA2887056C CA 2887056 C CA2887056 C CA 2887056C CA 2887056 A CA2887056 A CA 2887056A CA 2887056 A CA2887056 A CA 2887056A CA 2887056 C CA2887056 C CA 2887056C
Authority
CA
Canada
Prior art keywords
potassium salt
fimasartan potassium
fimasartan
salt monohydrate
crystalline form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2887056A
Other languages
English (en)
French (fr)
Other versions
CA2887056A1 (en
Inventor
Je Hak Kim
Ji Han Kim
Joon Kwang Lee
Byoung Wug Yoo
Nam Seok Han
Kyung Wan Nam
Chang Mo Kim
Joo Han Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boryung Pharmaceutical Co Ltd
Original Assignee
Boryung Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boryung Pharmaceutical Co Ltd filed Critical Boryung Pharmaceutical Co Ltd
Publication of CA2887056A1 publication Critical patent/CA2887056A1/en
Application granted granted Critical
Publication of CA2887056C publication Critical patent/CA2887056C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA2887056A 2012-10-12 2013-10-11 Monohydrate crystal of fimasartan potassium salt, method for preparing same, and pharmacological composition comprising same Expired - Fee Related CA2887056C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2012-0113848 2012-10-12
KR20120113848A KR101490329B1 (ko) 2012-10-12 2012-10-12 피마살탄 포타슘염의 일수화물 결정, 그 제조방법, 및 그를 포함하는 약제학적 조성물
PCT/KR2013/009097 WO2014058268A1 (ko) 2012-10-12 2013-10-11 피마살탄 포타슘염의 일수화물 결정, 그 제조방법, 및 그를 포함하는 약제학적 조성물

Publications (2)

Publication Number Publication Date
CA2887056A1 CA2887056A1 (en) 2014-04-17
CA2887056C true CA2887056C (en) 2017-09-05

Family

ID=50477658

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2887056A Expired - Fee Related CA2887056C (en) 2012-10-12 2013-10-11 Monohydrate crystal of fimasartan potassium salt, method for preparing same, and pharmacological composition comprising same

Country Status (13)

Country Link
EP (1) EP2927226A4 (OSRAM)
KR (1) KR101490329B1 (OSRAM)
CN (1) CN104854099B (OSRAM)
AU (1) AU2013330603B2 (OSRAM)
BR (1) BR112015008170A2 (OSRAM)
CA (1) CA2887056C (OSRAM)
IN (1) IN2015DN03975A (OSRAM)
MX (1) MX353635B (OSRAM)
MY (1) MY169064A (OSRAM)
PH (1) PH12015500794A1 (OSRAM)
RU (1) RU2613555C2 (OSRAM)
SA (1) SA515360275B1 (OSRAM)
WO (1) WO2014058268A1 (OSRAM)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101545268B1 (ko) 2015-02-05 2015-08-20 보령제약 주식회사 정제 및 이의 제조방법
CN105784867B (zh) * 2016-03-28 2019-01-01 北京睿创康泰医药研究院有限公司 用于分析非马沙坦有关物质的hplc方法及这些杂质作参比标准的用途
KR102247408B1 (ko) 2017-09-18 2021-05-03 보령제약 주식회사 피마살탄 프로드러그
KR102402501B1 (ko) * 2018-04-24 2022-05-26 (주)국전약품 피마살탄 트로메타민염 및 이를 포함하는 약제학적 조성물
KR102221856B1 (ko) 2020-10-12 2021-03-02 유니셀랩 주식회사 신규한 피마살탄 결정형의 다형체
KR20230062916A (ko) 2021-11-01 2023-05-09 그린케미칼 주식회사 피마살탄 무수물 a형 결정다형 및 그 제조방법
KR20230062917A (ko) 2021-11-01 2023-05-09 그린케미칼 주식회사 피마살탄 일수화물 b형 결정다형 및 그 제조방법
KR20240146734A (ko) 2023-03-30 2024-10-08 (주) 에프엔지리서치 피마살탄의 신규 염 및 이의 제조방법

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100300566B1 (ko) * 1994-09-17 2001-11-22 조생현 피리미디논유도체와그의제조방법및용도
KR19990081093A (ko) * 1998-04-25 1999-11-15 조생현 피리미디논 화합물, 이를 함유하는 약제학적 조성물 및 이의제조방법
KR100617953B1 (ko) 2000-03-23 2006-08-30 보령제약 주식회사 피리미디논 화합물 및 이의 염의 제조방법
WO2003024956A1 (en) * 2001-09-21 2003-03-27 Boryung Pharmaceutical Co., Ltd. Method for preparing pyrimidinone compound and pharmaceutically acceptable salts thereof
KR100521980B1 (ko) * 2002-10-10 2005-10-17 보령제약 주식회사 피리미디논 화합물 및 이의 염의 삼수화물의 제조 방법
SG194162A1 (en) * 2011-04-12 2013-11-29 Boryung Pharm Antihypertensive pharmaceutical composition

Also Published As

Publication number Publication date
KR101490329B1 (ko) 2015-02-04
CN104854099B (zh) 2016-11-16
AU2013330603A1 (en) 2015-05-28
BR112015008170A2 (pt) 2017-07-04
EP2927226A4 (en) 2016-07-13
AU2013330603B2 (en) 2016-03-31
MX353635B (es) 2018-01-22
RU2613555C2 (ru) 2017-03-17
PH12015500794A1 (en) 2015-06-15
CN104854099A (zh) 2015-08-19
EP2927226A1 (en) 2015-10-07
MX2015004573A (es) 2015-07-21
IN2015DN03975A (OSRAM) 2015-10-02
RU2015117524A (ru) 2016-12-10
MY169064A (en) 2019-02-12
SA515360275B1 (ar) 2017-07-11
WO2014058268A1 (ko) 2014-04-17
CA2887056A1 (en) 2014-04-17
KR20140047483A (ko) 2014-04-22

Similar Documents

Publication Publication Date Title
CA2887056C (en) Monohydrate crystal of fimasartan potassium salt, method for preparing same, and pharmacological composition comprising same
EP3969449B1 (en) New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer
CN104736526B (zh) 沃替西汀盐及其晶体、它们的制备方法、药物组合物和用途
US10954223B2 (en) Canagliflozin monohydrate and its crystalline forms, preparation methods and uses thereof
EP2639234A1 (en) Crystalline 6,7-unsaturated-7-carbamoyl morphinane derivative, and method for producing same
CN112142679B (zh) 一种吉非替尼与香草酸共晶甲醇溶剂合物及其制备方法
CN119523922A (zh) 用于口服的包含氨基嘧啶衍生物或其盐的药物组合物
EP2651952A2 (en) Polymorphic forms of asenapine maleate and processes for their preparation
CN111094290A (zh) 瑞博西尼的单琥珀酸盐晶型及其制备方法和用途
WO2012114325A1 (en) Polymorphs of asenapine maleate
JP2024542840A (ja) Ｆｇｆｒ阻害剤の固体状形態
US9682988B2 (en) Solid salt form of α-6-mPEG6-O-hydroxycodone as opioid agonists and uses thereof
CN108440456B (zh) 奥利司他与有机酸钙的共晶体及包含该共晶体的药物组合物
CN105228988B (zh) 曲格列汀半琥珀酸盐的晶体及其制备方法和药物组合物
EP2945948B1 (en) Crystalline form ii of anagrelide hydrochloride monohydrate
EP2832723B1 (en) Stabilised amorphous forms of Saxagliptin
WO2015107545A1 (en) Water soluble salts of dasatinib hydrate
EP1713769B1 (en) Amorphous tamsulosin hydrochloride
JP5608666B2 (ja) ２種のピノセンブリン、その製造方法、および、医薬組成物の製造におけるその使用
CN106995431A (zh) 一种瑞普拉生水合物晶型及其制备方法和用途

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20150407

MKLA Lapsed

Effective date: 20201013